Coverage · Recent News · Press Resources
Recent coverage, announcements, and the resources journalists need to write about the work.
New publication on FDA regulatory strategy, frontier therapeutics, and capital decisions in healthcare. Read at thehillmanletter.substack.com.
The private family office founded in Dallas in 1995 continues its focus on inflammation, damaged tissue, and tumor-based cancer platforms grounded in FDA biologics pathway thinking.
Targeted Osmotic Lysis explainer and mechanism walkthrough goes live. TOL is investigational, is not FDA-approved, and has no registered clinical trial. See fixcancer.org.
Live. A $1,000 essay-contest scholarship for undergraduate students on the path to an entrepreneurial career, open nationwide. Launched in March 2025. Apply at andrewhillmanscholarship.com. Releases are listed on the press page.
Live. A $1,000 essay-contest grant for undergraduate students building a career in biotechnology. Announced in February 2026. The 2026 application cycle opened in May. Apply at andrewhillmangrant.com.
Verified bio at three lengths, fact sheet, speaking topics, headshots, downloads. Open the press kit.
The primary-source operating record and timeline at andrewhillmanrecord.com. Verified directly, no PR filter.
For interviews, press, podcasts, and quote requests: contact@andrew-hillman.com. Direct response.
FDA biologics pathway, exosome regulatory science, family office structure, compliance, Dallas biotech ecosystem.
Exosome and mesenchymal stem cell-derived extracellular vesicle products are not approved by the FDA for any indication. References here describe published scientific literature. They do not describe an available treatment.
Andrew Jonathan Hillman
Dallas senior paralegal and healthcare compliance expert witness. Not an attorney.